title: Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.
authors.forename: Ersi
authors.initials: E
authors.lastname: Voskaridou
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Christoulas
authors.forename: Marialena
authors.initials: M
authors.lastname: Konstantinidou
authors.forename: Evangelos
authors.initials: E
authors.lastname: Tsiftsakis
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Alexakos
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D010146:Pain; D013789:Thalassemia / Q000097:blood / Q000150:complications*; D013997:Time Factors; D000077211:Zoledronic Acid
chemical_list: D015415:Biomarkers; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid